International Journal of Enhanced Research in Science, Technology & Engineering
ISSN: 2319-7463, Vol. 8 Issue 6, June -2019, Impact Factor: 4.059

Potential of β-Lactamase Inhibitors in Perspective of Antibiotic Resistance

Dr. Aarti Trehan

Associate Professor, Chemistry Department, Arya Kanya Mahavidyalaya, Shahabad (M), Kurukshetra-136135, India

ABSTRACT

β-lactam antibiotics represent a crucial class of antimicrobials that have shaped modern medicine and continue to play a pivotal role in the treatment of bacterial infections. Antibiotic resistance is a global health crisis that threatens our ability to effectively treat bacterial infections. One significant mechanism of resistance involves the production of β-lactamase enzymes by bacteria. β-lactamases can hydrolyze and inactivate beta-lactam antibiotics, rendering them ineffective. To combat this challenge, researchers have developed beta-lactamase inhibitors, which work in combination with beta-lactam antibiotics to restore their effectiveness against resistant bacteria. This study explores the potential of β-lactamase inhibitors in the context of antibiotic resistance, highlighting their role, mechanisms of action, and clinical significance.

INTRODUCTION

β-lactams remain essential and widely used antibiotics in modern medicine. Their diverse spectrum of activity and efficacy against a wide range of bacterial pathogens make them indispensable tools in treating common infections, from respiratory and urinary tract infections to skin and soft tissue infections[1].β-lactam antibiotics, often referred to simply as beta-lactams, are a prominent and widely used class of antibiotics with a unique chemical structure. They owe their name to the presence of a β -lactam ring in their molecular structure, which is critical to their antimicrobial activity. β-lactams are highly effective in treating various bacterial infections and have been instrumental in saving countless lives since their discovery. They still remain an important and highly utilized class of antibiotics as the utility of these antibiotics remains important, not only in the human clinical situation butalso in a wide array of veterinary uses[1].The discovery of the first β-lactam antibiotic, penicillin, by Alexander Fleming in 1928 revolutionized the field of medicine and marked the beginning of the antibiotic era. Over the years, researchers have developed various subclasses of β-lactams, such as penicillins, cephalosporins, monobactams, and carbapenems, each with its distinct spectrum of activity and clinical applications[2].The primary mechanism of action of β-lactam antibiotics is their ability to inhibit bacterial cell wall synthesis. They target penicillin-binding proteins (PBPs), enzymes responsible for cross-linking peptidoglycan, a critical component of the bacterial cell wall. By binding irreversibly to PBPs, β-lactams interfere with the formation of a stable cell wall, leading to cell lysis and bacterial death.



Fig. 1: Usage of parenteral β-Lactam by class from 2004-2014 in the United States[a]

[a]The percentage for each injectable antibiotic class prescribed in the United States from 2004 to 2014. (Data from the IMS MDART Quarterly Database on file at AstraZeneca.)

β-lactam antibiotics are a class of antibiotics that contain a beta-lactam ring in their chemical structure. They are widely used in clinical practice and encompass several subclasses, including penicillins, cephalosporins, monobactams, and carbapenems (Figure 1).

Subclasses of β-Lactam Antibiotics

The most widely used antibiotics for treating a variety of bacterial infections are β-lactam antibiotics, which work by preventing the formation of the bacterial cell wall. Penicillin and other β-lactam antibiotics are arguably the most significant medications ever due to their ability to treat bacterial infections and have a favorable effect on health globally[3]. The sub classes are following and basic structure is given in Table1:

- Penicillins: Penicillins were the first class of beta-lactam antibiotics to be discovered. They include narrow-spectrum penicillins (e.g., penicillin G and penicillin V) effective against Gram-positive bacteria, and extended-spectrum penicillins (e.g., ampicillin and amoxicillin) with additional activity against some Gram-negative bacteria.
- Cephalosporins: Cephalosporins have a similar structure to penicillins but exhibit broader activity against Gram-positive and Gram-negative bacteria. They are classified into several generations based on their spectrum of activity and resistance to beta-lactamases.
- Monobactams: Monobactams, such as aztreonam, are effective primarily against Gram-negative bacteria. They are resistant to most beta-lactamases produced by Gram-negative organisms.
- Carbapenems: Carbapenems, including imipenem, meropenem, doripenem, and ertapenem, have a broad spectrum of activity against both Gram-positive and Gram-negative bacteria. They are often reserved for severe infections or when other antibiotics are ineffective.

Table 1: Subclasses of β-Lactam Antibiotics

S. No.	Name of β- lactam Antibiotic	Structure
1.	Penicillins	
2.	Carbapenems	
3.	Cephalosporins	
4.	Monobactams	

β-lactam antibiotics and resistance

The fact that β-lactam antibiotics can kill a wide range of bacteria and have very low toxicity to humans suggests that there is a serious threat from β-lactam resistance[4]. Bacteria and other infection-causing microbes have remarkably developed a number of ways to develop resistance to antibiotics and other antimicrobial drugs. This is primarily due to the increased usage and abuse of antibiotics for various medical conditions[5].Antimicrobial resistance has emerged by the dangerous usage of these antibiotics. Due to the rising death rate and extended

hospital stays, this antibiotic resistance is becoming a serious health risk in addition to higher clinical costs. Due to rising antibiotic resistance, an increasing number of common diseases have been identified, primarily respiratory tract infections, sexually transmitted infections, blood infections, and urinary tract infections. By 2050, if this trend continues, antibiotic resistance may be responsible for 10 million annual fatalities. Antibiotic resistance is a complex and pressing global health challenge that occurs when bacteria and other microorganisms develop mechanisms to withstand the effects of antibiotics. It is a natural evolutionary process driven by the selective pressure exerted by antibiotic use. While β-lactams have been significantly successful in treating bacterial infections, the emergence of antibiotic resistance has posed significant challenges. Bacteria can develop resistance to β-lactams through mechanisms such as the production of beta-lactamase enzymes, which can inactivate the antibiotics by breaking the beta-lactam ring. Effectiveness of one of the most frequently prescribed drug groups, i.e., β-lactam antibiotics, have been constrained by the introduction of bacteria with a wide range of resistance. Several factors contribute to the emergence and spread of antibiotic resistance:

- Overuse and Misuse of Antibiotics
- Poor Infection Control Practices
- Lack of New Antibiotics
- Global Travel and Trade

Mechanisms of Antibiotic Resistance

Beta-lactam antibiotics typically work by blocking the enzyme necessary for the formation of the bacterial cell wall[6].The fundamental mechanism of β-lactam resistance is reactions involving the cleavage of the antibiotic's β-lactam ring by bacterial β-lactamases[7].To understand the potential of beta-lactamase inhibitors, it's essential to delve into the mechanisms of antibiotic resistance and the role of beta-lactamases. Antibiotic resistance occurs when bacteria acquire genetic mutations or acquire genes from other bacteria, allowing them to survive and multiply in the presence of antibiotics. One common mechanism of resistance is the production of beta-lactamases, which hydrolyze the four-membered beta-lactam ring present in beta-lactam antibiotics. This ring is crucial for the antibiotic's ability to inhibit bacterial cell wall synthesis.



Bacteria can develop resistance to antibiotics through several mechanisms, including:

- Mutation: Bacteria can acquire genetic mutations that alter their target sites, making them less susceptible to the antibiotics. Mutations can also occur in the genes responsible for drug uptake or efflux, reducing the antibiotic's effectiveness.
- Horizontal Gene Transfer: Bacteria can transfer resistance genes horizontally to other bacteria, both within and between species. This transfer can occur through plasmids, transposons, or other mobile genetic elements, allowing the spread of resistance genes among bacterial populations.
- Enzymatic Inactivation: Bacteria produce enzymes, such as beta-lactamases, which can break down or modify antibiotics, making them inactive. Due to the structural similarity between beta-lactamases and PBP, bacteria produce enzymes known as beta-lactamases that hydrolyze the beta-lactam ring, rendering the antibiotic inactive before it reaches the PBP target[8]. These enzymes can be constitutively produced or induced by exposure to antibiotics.
- Efflux Pumps: Bacteria can possess efflux pumps that actively pump out antibiotics from within the cell, reducing their intracellular concentration and efficacy.Efflux pumps are a type of acquired or innate resistance trait. The periplasmic region of the cell can export a variety of substrates to the environment through efflux pumps[9]. Multidrug resistance is determined by these pumps.

Antibiotic Resistance and β-lactamase inhibitors

While antibiotic resistance remains a pressing concern, the development of beta-lactamase inhibitors and ongoing research efforts offer hope in overcoming this challenge and preserving the effectiveness of beta-lactams in the fight against infectious diseases. β-lactamase inhibitors are compounds that bind irreversibly to beta-lactamases, preventing them from breaking down beta-lactam antibiotics. By inhibiting the action of beta-lactamases, these inhibitors protect the beta-lactam antibiotics, allowing them to exert their antimicrobial activity. This combination

therapy provides a powerful strategy to overcome antibiotic resistance and expand the utility of beta-lactam antibiotics.

Mechanism of actionβ-lactamase inhibitors

β-lactamase inhibitors offer great potential in addressing antibiotic resistance. By protecting β-lactam antibiotics from degradation by β-lactamases, these inhibitors restore their effectiveness against resistant bacteria. Their broad-spectrum activity, synergistic effects, ability to reduce selection pressure, and potential for combination therapies make them valuable tools in combating antibiotic resistance. Ongoing research and development efforts aim to further improve and optimize beta-lactamase inhibitors to address emerging resistance challenges and ensure effective treatment options in the future. β-lactamase inhibitors work by irreversibly binding to beta-lactamases[10-12], which are enzymes produced by bacteria that can hydrolyze the β-lactam ring present in beta-lactam antibiotics. The binding of the inhibitor to the β-lactamase prevents its interaction with the antibiotic, allowing the antibiotic to remain active and effectively target the bacteria. Essentially, β-lactamase inhibitors protect beta-lactam antibiotics from degradation by beta-lactamases, restoring their efficacy.Recent studies being conducted to clarify the mechanics of beta-lactamase inhibition of diacylation-deficient β-lactamases will undoubtedly increase our understanding of the chemistry of inactivation[13].

Classes of β-lactamase inhibitors

β-lactamase inhibitors are designed to bind irreversibly to beta-lactamases, preventing them from hydrolyzing beta-lactam antibiotics. By inhibiting the action of beta-lactamases, these inhibitors restore the efficacy of beta-lactam antibiotics against resistant bacteria. This combination therapy, known as a beta-lactamase inhibitor-antibiotic combination, provides a two-pronged attack on bacteria by inhibiting the resistance mechanism and allowing the antibiotic to exert its antibacterial activity..There are several classes of beta-lactamase inhibitors, including clavulanic Acid, Sulbactam, Tazobactam and Avibactam whose structure and partner β-lactam have been given in Table 2.

- Clavulanic Acid: Clavulanic acid was the first beta-lactamase inhibitor discovered and is widely used in combination with amoxicillin to create amoxicillin/clavulanate, also known as Augmentin. Clavulanic acid effectively inhibits a broad range of beta-lactamases, including some of the most common ones produced by Gram-positive and Gram-negative bacteria.
- Sulbactam: Sulbactam is commonly used in combination with ampicillin to create ampicillin/sulbactam (Unasyn). It exhibits activity against certain beta-lactamases, particularly those produced by Gram-negative bacteria such as Escherichia coli and Klebsiella pneumoniae.
- Tazobactam: Tazobactam is frequently used in combination with piperacillin to create piperacillin/tazobactam (Zosyn). It has a broad spectrum of beta-lactamase inhibitory activity, including against some extended-spectrum beta-lactamases (ESBLs) produced by Gram-negative bacteria.
- Avibactam: Avibactam is a newer beta-lactamase inhibitor that has been developed to combat resistance, especially against Gram-negative bacteria. It demonstrates potent activity against a wide range of beta-lactamases, including ESBLs and some carbapenemases. Avibactam is used in combination with ceftazidime to create ceftazidime/avibactam (Avycaz).

Key potentials β-lactamase inhibitors

The clinical utility of β-lactam antibiotics has been significantly enhanced due to β-lactamase inhibitors. Major key potential areas of β-lactamase inhibitor are as under:

- Restoring Antibiotic Efficacy: The primary purpose of beta-lactamase inhibitors is to restore the efficacy of beta-lactam antibiotics, such as penicillins and cephalosporins, against bacteria that produce beta-lactamase enzymes. By inhibiting the action of these enzymes, beta-lactamase inhibitors allow antibiotics to remain active against a broader range of bacteria, including those that would otherwise be resistant.
- Combating Antibiotic Resistance: The use of beta-lactamase inhibitors in combination with antibiotics helps combat antibiotic resistance, particularly in the context of beta-lactamase-mediated resistance. This approach expands the spectrum of bacteria that can be effectively treated with existing antibiotics, reducing the reliance on more potent, broad-spectrum antibiotics and slowing the development of resistance.
- Treatment of Resistant Infections: Beta-lactamase inhibitors are instrumental in treating infections caused by multidrug-resistant bacteria. They provide a therapeutic option when other antibiotics may be ineffective due to resistance mechanisms like beta-lactamase production.

Table 2: Classes of β-Lactamase Inhibitors

Name	Structure	Subclass	Partner β-lactam	Status
Clavulanic acid		Clavam	Amoxicillin	Widely available
Sublactam		Penicillanic acid sulfone	Ampicillin	Widely available
Tazobactam		Penicillanic acid sulfone	Pipreacillin Ceftolozane &	Widely available in US
Avibactam		DBO	Ceftazidime	Widely available

- Synergistic Effects: The combination of beta-lactam antibiotics with beta-lactamase inhibitors can have synergistic effects, meaning that the two components together are more effective at killing bacteria than either component alone. This synergy enhances the therapeutic potential of beta-lactam antibiotics.
- Reduced Need for Stronger Antibiotics: Beta-lactamase inhibitors can help reduce the need for stronger, more potent antibiotics that may have a broader spectrum of activity and a higher risk of side effects. This can lead to more targeted and appropriate antibiotic use.
- Lower Treatment Costs: Effectively treating infections with beta-lactamase inhibitors can be more cost-effective than using expensive, last-resort antibiotics. It can also lead to shorter hospital stays and lower overall healthcare costs.
- Preservation of Antibiotic Classes: The use of beta-lactamase inhibitors helps preserve the effectiveness of beta-lactam antibiotics, which are among the most commonly prescribed antibiotics worldwide. Preserving the utility of these antibiotics is crucial for patient care.
- Customized Treatment: Beta-lactamase inhibitors can be tailored to specific bacterial infections based on their resistance profiles. This allows for more precise and individualized treatment regimens.
- In summary, the potential of beta-lactamase inhibitors lies in their ability to address antibiotic resistance, expand treatment options, and improve the effectiveness of beta-lactam antibiotics. These inhibitors are valuable tools in the fight against bacterial infections and play a vital role in modern healthcare practices.

Advantages of β-lactamase inhibitors

β-lactamase inhibitors play a vital role in restoring the activity of beta-lactam antibiotics against resistant bacteria. β-lactamase inhibitors have many advantages many of which have been discussed below:

- β-lactamase inhibitors show broad-spectrum activity. They are effective against a wide range of beta-lactamases produced by different bacteria, including common ones such as extended-spectrum beta-lactamases (ESBLs) and AmpC beta-lactamases. This broad coverage enables the treatment of infections caused by resistant bacteria across various clinical settings.
- The combination of a beta-lactamase inhibitor with a beta-lactam antibiotic also leads to a synergistic effect. The inhibitor protects the antibiotic from degradation, enhancing its antibacterial activity. This synergy translates into improved clinical outcomes and increased treatment success rates, particularly in infections caused by resistant strains.

- The use of beta-lactamase inhibitors helps reduce the selection pressure for the emergence of resistance. When bacteria are exposed to suboptimal antibiotic concentrations due to resistance, there is a higher likelihood of resistance mutations occurring. However, effective treatment with combination therapy reduces the selective advantage for resistant strains, slowing down the development of resistance.
- The β-lactamase inhibitors not only restore the effectiveness of beta-lactam antibiotics but also have the potential to broaden the spectrum of activity. Some inhibitors can inhibit additional resistance mechanisms, such as efflux pumps, which are responsible for pumping out antibiotics from bacterial cells. By addressing multiple resistance mechanisms simultaneously, beta-lactamase inhibitors provide a valuable approach to combat multidrug-resistant bacteria.

FUTURE PERSPECTIVES

Developments in the field of β- lactams[14-15]during the years have shown that the only essential feature for antibacterial activity is the presence of β- lactam ring. Hence attention has to be focused on these four membered cyclic amides. β-lactamase inhibitors have significant potential in combating antibiotic resistance by restoring the activity of beta-lactam antibiotics against resistant bacteria. They offer broad-spectrum activity, synergistic effects, reduced selection pressure, and the potential for combination therapies. While they are not a definitive solution to antibiotic resistance, their use represents an important tool in the arsenal against resistant bacterial infections. As antibiotic resistance continues to evolve, the development of new beta-lactamase inhibitors remains an active area of research. Scientists are working on novel inhibitors with enhanced activity against a broader range of beta-lactamases, including emerging resistance mechanisms like carbapenemases.

Combination therapies that utilize multiple beta-lactamase inhibitors or combine beta-lactamase inhibitors with other novel antibiotic classes are also being explored to address challenging cases of antibiotic resistance. Additionally, efforts are being made to improve the pharmacokinetic properties of beta-lactamase inhibitors to ensure optimal drug concentrations at the infection site. This includes modifying the structure of inhibitors to enhance stability, bioavailability, and tissue penetration, thereby maximizing their clinical efficacy. Thus, beta-lactamase inhibitors have revolutionized the management of antibiotic resistance. Ongoing research aims to develop new inhibitors and combination therapies to combat emerging resistance mechanisms and ensure effective treatment options in the future. Their clinical significance lies in expanding the spectrum of activity, improving treatment outcomes, and combating the challenge of antibiotic resistance.

REFERENCES

[1]. Babic M. A., Hujer M., Bonomo R. A., (2006), What's new in antibiotic resistance? Focus on beta-lactamases. *Drug Resist Updat.* 9, 142–156.
[2]. Holten K. B., Onusko E.M.,(2000), Appropriate prescribing of oral beta-lactam antibiotics. *American family physician*. 62(3), 611–620.
[3]. Kardos N., Demain A. L., (2011). Penicillin: the medicine with the greatest impact on therapeutic outcomes. *Appl Microbiol Biotechnol*. 92, 677–687.
[4]. Livermore D. M., (1996). Are all beta-lactams created equa?*Scand J Infect. Dis.* .101(l):33–43.
[5]. Kumarasamy K. K., Toleman M. A., Walsh T. R., et al (2010). Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: A molecular, biological, and epidemiological study. *Lancet Infect Dis.*.10:597–602.
[6]. 6.Massova I., Mobashery S., (1998). Kinship and diversification of bacterial penicillin-binding proteins and beta-lactamases. *Antimicrob.Agents Chemother*. 42:1-17
[7]. Medeiros A. A., (1997). Evolution and dissemination of beta-lactamases accelerated by generations of beta-lactam antibiotics. *Clin Infect Dis.* 24:19–45.
[8]. Massova I., Mobashery S., (1998). Kinship and diversification of bacterial
[9]. penicillin-binding proteins and beta-lactamases. *Antimicrob Agents Chemother*. 42:1–17.
[10]. Poole K., (2004). Efflux-mediated multiresistance in Gram-negative bacteria. Clin Microbiol Infect. 10:12–26.
[11]. Helfand. M. S., Totir. M. A., Carey. M. P.,(2003). Following the reactions of mechanism-based inhibitors with beta-lactamase by Raman crystallography. *Biochemistry.* 42:13386–13392.
[12]. Padayatti P.S., Helfand M.S., Totir M. A., (2004). Tazobactam. Forms a stoichiometric trans-enamine intermediate in the E166A variant of SHV 1 beta-lactamase: 1.63 A crystal structure. Biochemistry. 43:843–848
[13]. Pagan R. D., Zhou X., Simmons R., (2004). Tazobactam inactivation of SHV-1 and the inhibitor-resistant Ser130→Gly SHV-1 beta-lactamase: insights into the mechanism of inhibition. *J Biol Chem. 279*:19494–19501.

[14]. Padayatti P. S., Helfand M. S., Totir M, A., (2005) High-resolution crystal structures of the trans-enamine intermediates formed by sulbactam and clavulanic acid and E166A SHV-1 beta-lactamase. *J Biol Chem.* 280:34900–34907.
[15]. Sharma S. D., Kaur V.,Saluja A., (1994). Synthesis and mechanismof formation of β-lactams from N-methyl imines.*Indian Journal of Chemistry*.33B, 624-628
[16]. 15.Trehan A., Trehan R., (2018)Antibiotic Resistance: A Looming Crisis of Concern,*Journal of Applied Science and Computations*, 5, 10, 1657-1664.